Omega Diagnostics Group PLC

finnCap Capital Markets has advised Omega Diagnostics on a placing of £5m with up to £2m possible via an Open Offer to enable it to focus on the growth opportunities within its two core businesses, Health & Nutrition and Global Health (VISITECT CD4). It has also sold its Alva site for £1m, with a transitionary agreement in place to December 2022 to ensure the continued production of lateral flow tests for Omega. A strategic review will be undertaken before committing to relocating CD4 activities to its new facility in Ely.